In January 2020 the Chiefs, Heads and Directors of the DNA Damage Response field will gather at the PARP & DNA Damage Response (DDR) Inhibitors Summit to push PARP into wider indications and accelerate novel target development. Hear from experts at Merck KGaA, Bayer, AstraZeneca and many more, as they race to find best-in-class PARPi and discuss novel and emerging targets in the exploding DDR field.
Equip yourselves with the knowledge and expertise to optimize your DNA Damage Response therapeutics, find the best combination strategies and overcome drug resistance. Learn from trailblazers such as Frank Zenke, Geoffrey Shapiro and Mitch Raponi, who will assemble to address key challenges and devise strategies to maximize the therapeutic potential of DDR targets.
This is the industry-focused end-to-end meeting to attend this year. A unique opportunity to meet with the VPs, Heads and Directors of Translational Oncology, Target Discovery and Early Drug Development to accelerate your DDR pipeline
Conference + 2 Workshops (Drug Developers) USD 3897.00
Conference + 1 Workshop (Drug Developers) USD 3398.00
Conference Only (Drug Developers) USD 2899.00
Workshop Only (Drug Developers) USD 599.00
Conference + 2 Workshops (Service Providers) USD 4697.00
Conference + 1 Workshop (Service Providers) USD 4098.00
Conference Only (Service Providers) USD 3499.00
Speakers: Alan D’Andrea, Professor, Radiation Oncology, Harvard Medical School, Ranjit Bindra, Associate Professor, Therapeutic Radiology and Pathology, Yale Brain Tumor Center, James Hansen, Associate Professor of Therapeutic Radiology, Yale School of Medicine, Françoise Bono, Chief Scientific Officer, Onxeo, Sui Xiong Cai, Chief Technology Officer, Impact Therapeutics, Geoffrey Shapiro, Director Early Drug Development Center, Dana-Faber Institute, Kevin Mills, Chief Scientific Officer, Cyteir, Asli Muvaffak, Scientific Team Leader, Synthetic Lethality, Tesaro: a GSK Company, Nashwa Kabil, Senior Medical Director DNA Damage Response, AstraZeneca, Sophia Gayle, Associate Director of Biology, Cybrexa Therapeutics, Mitch Raponi, Vice President, Biomarkers & Translational Research, BeiGene, Patrick Pilié, Assistant Professor, Genitourinary Medical Oncology, MD Anderson Cancer Center, Eleni Lagkadinou, Vice President, Translational Medical Oncology, Bayer, Daniel Speidel, Co-Managing Director, Breakpoint Therapeutics, Helen Robinson, Head of Biology, Artios Pharma, Neil Bhola, Senior Scientist, IDEAYA Biosciences, Junjie Chen, Professor, Experimental Radiation Oncology, MD Anderson Cancer Center, Jaegil Kim, Senior Principle Scientist Senior Principle Scientist, Tesaro: a GSK Company, Anish Thomas, Investigator, National Cancer Institute, Frank Zenke, Head of DNA Damage Response Research, Merck KGaA, Sabita Sankar, Business Development Manager, Ambry Genetics, Victoria Richon, President & Chief Executive Officer, Ribon Therapeutics